G1 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 100
- Market Cap
- $376.1M
Clinical Trials
50
Trial Phases
4 Phases
Drug Approvals
2
Drug Approvals
Trilaciclib Hydrochloride for Injection
- Product Name
- 科赛拉
- Approval Number
- 国药准字HJ20220066
- Approval Date
- Jul 12, 2022
Clinical Trials
Distribution across different clinical trial phases (47 trials with phase data)• Click on a phase to view related trials
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05874401
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee, Klagenfurt am Worthersee, Austria
🇦🇹Klinik Hietzing, Vienna, Austria
🇦🇹Wiener Gesundheitsverband Klinik Penzing, Wien, Austria
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05113966
- Locations
- 🇺🇸
Ironwood Physicians, Chandler, Arizona, United States
🇺🇸Comprehensive Blood & Cancer Center, Bakersfield, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- Conditions
- Breast CancerTriple Negative Breast Cancer
- Interventions
- Drug: CylophosphamideBiological: Pembrolizumab (Investigator discretion)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05112536
- Locations
- 🇺🇸
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸PIH Health, Whittier, California, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- Conditions
- Myelosuppression AdultBladder CancerUrothelial CarcinomaChemotherapy-induced NeutropeniaMetastatic Bladder Cancer
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT04887831
- Locations
- 🇺🇸
Valkyrie Clinical Trial, Los Angeles, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸Rocky Mountain Cancer Centers, Littleton, Colorado, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Conditions
- NSCLCMetastatic Non-Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04863248
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers, Phoenix, Arizona, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Desert Hematology Oncology Medical Group, Inc, Rancho Mirage, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Genor Biopharma Secures NMPA Approval for Lerociclib CDK4/6 Inhibitor in Advanced Breast Cancer
Genor Biopharma Holdings Ltd. received China National Medical Products Administration (NMPA) approval for Lerociclib (GB491), a novel CDK4/6 inhibitor for advanced breast cancer treatment.
mTNBC Pipeline Shows Promise with Novel Therapies in Clinical Trials
• The mTNBC pipeline includes over 12 drugs from 10+ companies, targeting novel approaches to improve treatment outcomes for this aggressive breast cancer. • Trilaciclib, a CDK4/6 inhibitor by G1 Therapeutics, is in Phase III trials to preserve bone marrow and immune function during chemotherapy in mTNBC patients. • Olinvacimab, an anti-angiogenic antibody by PharmAbcine/Merck, is in Phase II trials, blocking the VEGF/VEGFR2 pathway to inhibit tumor growth and metastasis. • Emerging therapies focus on intravenous, subcutaneous, and oral routes of administration, with molecule types including monoclonal antibodies and small molecules.
Pharmacosmos Completes Strategic Acquisition of G1 Therapeutics in Multi-Million Dollar Deal
Danish pharmaceutical company Pharmacosmos has finalized its acquisition of US-based G1 Therapeutics, gaining ownership of the cancer drug Cosela in a deal valued at over half a billion kroner.
Pharmacosmos Group Acquires G1 Therapeutics for $405 Million to Expand COSELA Access for Cancer Patients
Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million.